Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabergoline

FDA-approved product (tablet, oral), marketed as Cabergoline, Dostinex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cabergoline
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hypothalamic neoplasm
  • Parkinson disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prolactine inhibitors; Dopamine agonists
FDA pharmacologic class
Ergot Derivative FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabergoline in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabergoline with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

    NCT00242008 · start 2004-12

    Registered record
    Registry ID
    NCT00242008
    Conditions
    Parkinson's Disease
    Interventions
    Rotigotine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-12
    Completion
    2005-07
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionRotigotine
    PhasePhase 3
    Registry statusCompleted

  • Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.

    NCT00174239 · start 2004-07

    Registered record
    Registry ID
    NCT00174239
    Conditions
    Parkinson Disease
    Interventions
    cabergoline; controlled-release levodopa / carbidopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2004-07
    Completion
    2005-09
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    Interventioncabergoline; controlled-release levodopa / carbidopa
    PhasePhase 4
    Registry statusTerminated

  • A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS

    NCT00625547 · start 2003-01

    Registered record
    Registry ID
    NCT00625547
    Conditions
    Restless Legs Syndrome
    Interventions
    cabergoline; levodopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-01
    Completion
    2004-12
    Enrolment
    361

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRestless Legs Syndrome
    Interventioncabergoline; levodopa
    PhasePhase 3
    Registry statusCompleted

  • Effect of Cabergoline on Weight and Glucose Tolerance

    NCT01395602 · start 2002-04

    Registered record
    Registry ID
    NCT01395602
    Conditions
    Body Weight; Impaired Glucose Tolerance in Obese
    Interventions
    Cabergoline; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2002-04
    Completion
    2011-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBody Weight; Impaired Glucose Tolerance in Obese
    InterventionCabergoline; placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions

    NCT00653055 · start 2001-08

    Registered record
    Registry ID
    NCT00653055
    Conditions
    To Determine Bioequivalence Under Fasting Conditions
    Interventions
    Cabergoline; Dostinex
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-08
    Completion
    2001-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTo Determine Bioequivalence Under Fasting Conditions
    InterventionCabergoline; Dostinex
    PhasePhase 1
    Registry statusCompleted